These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26657922)

  • 1. Cardiorenal Syndrome in End-Stage Kidney Disease.
    Tsuruya K; Eriguchi M; Yamada S; Hirakata H; Kitazono T
    Blood Purif; 2015; 40(4):337-43. PubMed ID: 26657922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.
    Charytan DM; Fishbane S; Malyszko J; McCullough PA; Goldsmith D
    Am J Kidney Dis; 2015 Aug; 66(2):196-205. PubMed ID: 25727384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment.
    Granata A; Clementi A; Virzì GM; Brocca A; de Cal M; Scarfia VR; Zanoli L; Ronco C; Corrao S; Malatino L
    Eur J Intern Med; 2016 May; 30():1-6. PubMed ID: 26961461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
    Piotr B; Mariusz S; Jacek R
    Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular disease and its relationship with chronic kidney disease.
    Liu M; Li XC; Lu L; Cao Y; Sun RR; Chen S; Zhang PY
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2918-26. PubMed ID: 25339487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaemia and early phase cardiovascular events on haemodialysis.
    Hayashi T; Joki N; Tanaka Y; Hase H
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():1-6. PubMed ID: 26456311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients.
    Lee SA; Lee MJ; Ryu GW; Jhee JH; Kim HW; Park S; Jung SY; Oh HJ; Park JT; Han SH; Kang SW; Yoo TH
    Osteoporos Int; 2016 Sep; 27(9):2717-2726. PubMed ID: 27216997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal syndrome type 4: insights on clinical presentation and pathophysiology from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI).
    Tumlin JA; Costanzo MR; Chawla LS; Herzog CA; Kellum JA; McCullough PA; Ronco C
    Contrib Nephrol; 2013; 182():158-73. PubMed ID: 23689661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: a comprehensive French nationwide cohort study.
    Halimi JM; de Fréminville JB; Gatault P; Bisson A; Gueguen J; Goin N; Sautenet B; Maisons V; Herbert J; Angoulvant D; Fauchier L
    Nephrol Dial Transplant; 2022 Nov; 37(12):2386-2397. PubMed ID: 35438794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins.
    Guo J; Lu L; Hua Y; Huang K; Wang I; Huang L; Fu Q; Chen A; Chan P; Fan H; Liu ZM; Wang BH
    Am J Physiol Heart Circ Physiol; 2017 Jul; 313(1):H1-H13. PubMed ID: 28411233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiorenal syndrome type 4: management.
    Clementi A; Virzì GM; Brocca A; de Cal M; Vescovo G; Granata A; Ronco C
    Blood Purif; 2013; 36(3-4):200-9. PubMed ID: 24496191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].
    Omata M; Fukagawa M; Kakuta T
    Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.
    Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M
    Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anemia as a risk factor for CKD and CVD].
    Tsuruya K; Hirakata H
    Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalent cardiac, renal and cardiorenal damage in patients with advanced abdominal aortic aneurysms.
    Barisione C; Garibaldi S; Brunelli C; Balbi M; Spallarossa P; Canepa M; Ameri P; Viazzi F; Verzola D; Lorenzoni A; Baldassini R; Palombo D; Pane B; Spinella G; Ghigliotti G
    Intern Emerg Med; 2016 Mar; 11(2):205-12. PubMed ID: 26510876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adolescents and Young Adults with Chronic or End-Stage Kidney Disease.
    Ferris ME; Miles JA; Seamon ML
    Blood Purif; 2016; 41(1-3):205-10. PubMed ID: 26765837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MICS, an easily ignored contributor to arterial calcification in CKD patients.
    Zhang K; Gao J; Chen J; Liu X; Cai Q; Liu P; Huang H
    Am J Physiol Renal Physiol; 2016 Oct; 311(4):F663-F670. PubMed ID: 27335374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?
    Cozzolino M; Ureña-Torres P; Vervloet MG; Brandenburg V; Bover J; Goldsmith D; Larsson TE; Massy ZA; Mazzaferro S;
    Nephrol Dial Transplant; 2014 Oct; 29(10):1815-20. PubMed ID: 24516228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.